Veranova A CDMO that manages complexity with confidence

Veranova A CDMO that manages complexity with confidence

X

[{"orgOrder":0,"company":"OrsoBio","sponsor":"Mitobridge","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Shionogi","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Phenex Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Yale University","pharmaFlowCategory":"D","amount":"$2.3 million","upfrontCash":"Undisclosed","newsHeadline":"OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Samsara BioCapital","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders","therapeuticArea":"Dermatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces Presentation of Five Abstracts at AASLD\u2019s The Liver Meeting\u00ae 2022 Highlighting Programs for Severe Metabolic Disorders","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by OrsoBio

OrsoBio
Developments
Full Screen View

OrsoBio

About, Contact Details

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

No Presentations

VIDEO(s)

No Video

DIGITAL CONTENT

1 News

1 News

DEVELOPMENTS

7 Drug(s) in Development

7 Drug(s) in Development

Developments

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Therapeutic Area

filter

Study Phase

Active Filter(s):

Filters

Reset Filter

All Developments

Companies By Therapeutic Area

Development Status

OrsoBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OrsoBio Announces First Patient Dosed in Phase 2 Clinical Trial of the ACC2 Inhibitor TLC-3595, a Potential Treatment for Type 2 Diabetes

Details:

TLC-3595 is a novel and selective ACC2 inhibitor designed to treat type 2 diabetes by increasing FAO, reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver

Lead Product(s): TLC-3595

Therapeutic Area: Endocrinology Product Name: TLC-3595

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 20, 2023

ASK
US

Upload
your Pipeline Activity

OrsoBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders

Details:

OrsoBio has recently acquired novel compounds and intellectual property for four programs, including inhibitors of acetyl-CoA carboxylase-2 (TLC-3595), liver X receptor, and aminocarboxymuconate semialdehyde decarboxylase, as well as a portfolio of mitochondrial protonophores.

Lead Product(s): TLC-3595

Therapeutic Area: Endocrinology Product Name: TLC-3595

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 03, 2022

ASK
US

Upload
your Pipeline Activity

OrsoBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OrsoBio Acquires ACMSD Inhibitor Program to Address Mitochondrial Dysfunction from Mitobridge, an Astellas Company

Details:

ACMSD is a key enzyme involved in the de novo synthesis of NAD+, which is critical to mitochondrial function via maintenance of cellular redox state. TLC-065, is being advanced for the treatment of a range of metabolic and inflammatory liver and kidney disorders.

Lead Product(s): TLC-065

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TLC-065

Highest Development Status: Preclinical Product Type: Undisclosed

Recipient: Mitobridge

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition November 02, 2022

ASK
US

Upload
your Pipeline Activity

OrsoBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OrsoBio Acquires Phase 2-Ready, Selective ACC2 Inhibitor from Shionogi & Co., Ltd. for the Treatment of Type 2 Diabetes

Details:

TLC-3595 (formerly S-723595), a novel and selective ACC2 inhibitor, is designed to treat type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver.

Lead Product(s): TLC-3595

Therapeutic Area: Endocrinology Product Name: TLC-3595

Highest Development Status: Phase I Product Type: Undisclosed

Recipient: Shionogi

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition November 02, 2022

ASK
US

Upload
your Pipeline Activity

OrsoBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals

Details:

TLC-2716 is a liver-targeted, inverse agonist of LXR that regulates plasma triglycerides and cholesterol via multiple mechanisms, including inhibition of DNL, increased clearance of triglyceride- and cholesterol-rich lipoproteins, and reduced intestinal lipid absorption.

Lead Product(s): TLC-2716

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716

Highest Development Status: Phase I Product Type: Small molecule

Recipient: Phenex Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition November 02, 2022

ASK
US

Upload
your Pipeline Activity

OrsoBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OrsoBio Announces Exclusive License to Intellectual Property Relating to Mitochondrial Protonophores for the Treatment of Severe Metabolic Disorders

Details:

TLC-1235, a novel, controlled-release mitochondrial protonophore, increases energy expenditure and is expected to have broad, systemic metabolic and cardiovascular benefits, including improved insulin sensitivity, NASH, dyslipidemia, and weight loss.

Lead Product(s): TLC-1235

Therapeutic Area: Dermatology Product Name: TLC-1235

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Yale University

Deal Size: $2.3 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement November 02, 2022

ASK
US

Upload
your Pipeline Activity

OrsoBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OrsoBio Initiates IND-Enabling Activities for Liver-Targeted Mitochondrial Protonophore TLC-6740 for the Treatment of Severe Metabolic Disorders

Details:

TLC-6740 is a novel, liver-targeted mitochondrial protonophore in development for the treatment of severe lipodystrophies and other metabolic disorders. Based on active hepatic uptake and mitochondrial protonophoric activity.

Lead Product(s): TLC-6740

Therapeutic Area: Dermatology Product Name: TLC-6740

Highest Development Status: IND Enabling Product Type: Small molecule

Partner/Sponsor/Collaborator: Samsara BioCapital

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2022

ASK
US

Upload
your Pipeline Activity

OrsoBio

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders

Details:

TLC-2716 is a liver-targeted inverse agonist of the Liver X Receptor (LXR) for the treatment of severe hypertriglyceridemia, familial hypercholesterolemia and NASH.

Lead Product(s): TLC-2716

Therapeutic Area: Cardiology/Vascular Diseases Product Name: TLC-2716

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 01, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY